Biostatistics Advance Access published online on June 19, 2006
Biostatistics, doi:10.1093/biostatistics/kxl009
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Swiss Laboratory for Doping Analyses, Université de Lausanne, 1066 Lausanne, Switzerland
* To whom correspondence should be addressed. We developed a test that compares sequential measurements of a biomarker against previous readings performed on the same individual. A probability mass function expresses prior information on inter-individual variations of intra-individual parameters. Then, the model progressively integrates new readings to more accurately quantify the characteristics of the individual. This Bayesian framework generalizes the two main approaches currently used in forensic toxicology for the detection of abnormal values of a biomarker. The specificity is independent of the number n of previous test results, with a model that gradually evolves from population-derived limits when n=0 to individual-based cut-off thresholds when n is large. We applied this model to detect abnormal values in an athlete's steroid profile characterized by the testosterone over epitestosterone (T/E) marker. A cross-validation procedure was used for the estimation of prior densities as well as model validation. The heightened sensitivity/specificity relation obtained on a large dataset shows that longitudinal monitoring of an athlete's steroid profile may be used efficiently to detect the abuse of testosterone and its precursors in sports. Mild assumptions make the model interesting for other areas of forensic toxicology.
Received March 24, 2006
Revised May 24, 2006
Accepted June 8, 2006
Article
Bayesian detection of abnormal values in longitudinal biomarkers with an application to T/E ratio
Pierre-Edouard Sottas 1 *,
Norbert Baume 1,
Christophe Saudan 1,
Carine Schweizer 1,
Matthias Kamber 2,
and
Martial Saugy 1
2 Swiss Federal Office for Sports BASPO, 2532 Macolin, Switzerland
Pierre-Edouard Sottas, E-mail: Pierre-Edouard.Sottas{at}hospvd.ch
![]()
Abstract ![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
L. D. Bowers The International Antidoping System and Why It Works Clin. Chem., August 1, 2009; 55(8): 1456 - 1461. [Full Text] [PDF] |
||||
![]() |
G. Lippi, W. E. Jelkmann, G. L. Salvagno, G. C. Guidi, C. R. Valeri, G. Ragno, B. Kayser, F. Lasne, Y. O. Schumacher, T. Pottgiesser, et al. Comments on Lundby et al.'s "testing for recombinant human erythropoietin in urine: problems associated with current anti-doping testing". Problems associated with current anti-doping testing: is quality assessment a reliable solution? J Appl Physiol, December 1, 2008; 105(6): 1992 - 1993. [Full Text] [PDF] |
||||
![]() |
L. D. Bowers Testosterone Doping: Dealing with Genetic Differences in Metabolism and Excretion J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2469 - 2471. [Full Text] [PDF] |
||||
![]() |
N. Robinson, P.-E. Sottas, P. Mangin, and M. Saugy Bayesian detection of abnormal hematological values to introduce a no-start rule for heterogeneous populations of athletes Haematologica, August 1, 2007; 92(8): 1143 - 1144. [Abstract] [Full Text] [PDF] |
||||



